Xaqua (metolazone) tablets launched in UK but not directly interchangeable with other metolazone products due to higher bioavailability

Xaqua is licensed for treatment of oedema related to kidney diseases & heart failure, and for mild/moderate hypertension, alone or in combination with other antihypertensive medicines. Bioavailability may differ significantly (up to~ 2-fold) from other metolazone products.

SPS commentary:

SPC advises that Xaqua tablets bioavailability may be different from other metolazone preparations. Therefore, the recommended doses (expressed in mg) can differ from other metolazone products. A dose adjustment may be necessary and individualised titration based on patient's response and tolerability is advised if switching from Xaqua tablets to another metolazone product, or vice versa.

electronic Medicines compendium